Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The GLP-1 CVD outcome trials a) Elixa (Lexisenatide) b) Leader (Liraglutide) c) Sustain-6 (Semaglutide) d) Exscel (Weekly Exenatide) e) Harmony (Albiglutide) f) Rewind (Dulaglutide) g) Pioneer 6 (Oral Semaglutide) Elixa Study (Evaluation of Lixisenatide) In ELIXA, the investigational GLP-1 receptor agonist, lixisenatide, neither reduced nor increased cardiovascular events compared with placebo
Related research has shown that ferroptosis is involved in septic cardiomyopathy both in vivo and in vitro and that upregulation of NCOA4 promoted ferritin autophagy and caused ferroptosis but that inhibiting autophagy reduces the occurrence of ferroptosis
2025 Sep 18:S1530-891X(25)00977-2
The first step is building a stronger foundation: nutrition, movement, sleep, and stress management
US$ 20.71
US$ 29.65
US$ 23.47
US$ 23.00
